Medication Information


Featured Articles

Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
Updated Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Training Slide Sets
Updated Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
FDA April 24, 2013
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines
Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (PDF)
Updated Hepatitis C Practice Guidelines Now Available from AASLD
ARLINGTON, Va., Sept. 28, 2011 /PRNewswire via COMTEX/
The updated Perinatal Guidelines (September 14, 2011) are Available
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
AIDSinfo Jan. 10, 2011
Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
FDA 07/22/2011
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-Analyses
Gastroenterology 30 July 2009
TAG 2010 Pipeline Report (PDF)
New FDA Hepatitis List Serve
Enhanced Drug Fact Sheets on AIDSInfo AETC National Resource Center
Reyataz (atazanavir) Package Insert Revisions

News Updates

HIV Email Updates
CDC | July 14, 2018
Patient‑Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double‑Blind, Phase III Non‑inferiority Trials of Adults with HIV on Co‑formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co‑formulated Abacavir, Dolutegravir, and Lamivudine
Hepatitis Update
FDA | July 5, 2018
Study: AIDS Drug Not Linked to Depression, Suicide
VOA Learning English | July 3, 2018
Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including ...
Business Wire | July 2, 2018
European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Business Wire | June 25, 2018
ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine
China approves Albuviritide: first domestically developed, long-acting injectable anti-HIV drug
Firstpost June 6, 2018
HIV Email Updates
FDA | June 5, 2018
Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for ...
GlobeNewswire | May 23, 2018
Elvitegravir pharmacokinetics during pregnancy and postpartum
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women  
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
U.S. Food and Drug Administration, Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG)
FDA | May 18, 2018
HIV Email Updates
May 15, 2018
Pediatric HIV Infection: Drug Development for Treatment
FDA | May 2018
2018 National Ryan White HIV/AIDS Program (RWHAP) Part B and ADAP Monitoring Project Annual Report
Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection
The International Liver Congress™ EASL - European Association for the Study of the Liver, Paris France, 11-15 April 2018
HIV Drug Appears Safe During Pregnancy
WebMD | April 25, 2018
HPV Vaccine Gardasil Is Not Effective in People With HIV Age 27 and Up
POZ | April 20, 2018
AIDSinfo Fact Sheets on New HIV Medications
AIDSinfo | April 19, 2018
Integrase inhibitors do not raise risk of IRIS in severely immunocompromised people
aidsmap | March 27, 2018
CytoDyn And HIV Therapy: CCR5 Antagonist Is An Old Drug Made New
Seeking Alpha | March 25, 2018
HIV Email Updates
Janssen Announces Positive CHMP Opinion for JULUCATM (dolutegravir/rilpivirine)
Business Wire | March 23, 2018
Insurer Denial of DAA Prescription Requests Rising Across United States
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
ISENTRESS Label Recently Updated
HIV Email Updates | March 8, 2018
FDA Approves TROGARZO to Treat HIV
HIV Email Updates | March 6, 2018
Clarithromycin (Biaxin): Drug Safety Communication - Potential Increased Risk of Heart Problems or Death in Patients With Heart Disease
FDA | February 22, 2018
PrEP does not raise lipids or alter body fat, safety study finds
aidsmap | February 15, 2018
NASTAD releases an updated 2018 Online AIDS Drug Assistance Program (ADAP) Formulary Database
Nano-Formulated Long-Acting Dolutegravir - cell/tissue/reservoir penetration
HIV Email Updates
FDA | February 7, 2018
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
GSK | February 8, 2018
Generic drugs for HIV treatment may save money, but barriers to prescription make savings elusive
aidsmap | February 7, 2018
High levels of antibiotic resistance found worldwide, new data shows
University of Minnesota | January 29, 2018
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
GuruFocus.com | February 1, 2018
Prezcobix Label Revised
FDA | Email Updates
Long-acting injectable ARVs are convenient and private, study participants report
aidsmap | January 17, 2018
Hiv & Diabetes - risk factors/ARTs
FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
BusinessWire | January 8, 2018
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
PLoS One. 2018 Jan 5;13(1):e0190487. doi: 10.1371/journal.pone.0190487. eCollection 2018
HIV Drugs in the Pipeline: Expected Approvals for 2018
Infectious Disease Special Edition | December 29, 2017
FDA Launches New Tool for Sharing Information That Allows Doctors to Better Manage Antibiotic Use; Improve Patient Care
FDA | December 13, 2017
Merck Receives FDA Approval for ISENTRESS® (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Newborns Weighing at Least 2 kg
Merck | November 29, 2017
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
ViiV | November 27, 2017
Four big insights into HIV/AIDS that provide hope of finding a vaccine
Medical Xpress | November 24, 2017
Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
Market Wired | November 13, 2017
HCV Advocate | November 13, 2017
NATAP | November 2017
HIV Email Update: FDA Approved Changes to the Genvoya Label
November 22, 2017
FDA approves first two-drug regimen for certain patients with HIV - Fixed Dose dolutegravir and rilpivirine
FDA | November 21, 2017
Tivicay® and Celsentri® now included in the Essential Drug List in Russia
Frequency of monitoring kidney function in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre-exposure prophylaxis
J Acquir Immune Defic Syndr. 2017 Nov 6. doi: 10.1097/QAI.0000000000001575

  Past Medication News Updates